IPCA LABORATORIES
Q1 FY 21 RESULTS REVIEW
About Ipca Laboratories:
Ipca is a fully integrated pharmaceutical company with a strong thrust on exports.
Ipca is vertically integrated and produces Finished Dosage Forms(FDFs) and Active Pharmaceutical Ingredients(APls).
Management
Premchand Godha Chairman & M.D & CEO
Ajit Kumar Jain Joint Managing Director & CFO
Key Financials of Ql FY21
• Standalone Net Total Income up 45% at Rs.1496.93crores.
• Consolidated Net Total Income up 41% at Rs.1546.49 crores.
• Indian formulations income up 8% at Rs.489.41 crores.
• Exports Income up 62% at Rs.773.89 crores.
• Standalone EBIDTA margin (before forex(gain)/Ioss) @39.65% in Q1 FY21 as against @19.91% in Q1 FY20.
• Consolidated EBIDTA margin @ 38.44% in Q1 FY21 as against @ 19.11% in Q1 FY20.
• Standalone Net Profit up 244% at Rs.453.64 cr.
• Consolidated Net Profit up 244% at Rs.445.68 cr
Q1 FY21 Revenue break-up (Rs. Cr)
Particulars Q1 FY21 Q1 FY20 Growth
Formulations
Domestic 489.41 452.81 8%
Exports
Branded 133.52 91.63 46%
Institutional 88.67 27.32 225%
Generics 241.45 125.87 92%
Total Formulations 953.05 697.63 37%
APls
Domestic 203.04 65.70 209%
Exports 310.25 232.63 33%
Total APls 513.29 298.33 72%
Subsidiaries 49.02 67.18 -27%
Other Operating Income 19.04 15.05 27%
Other Income 12.09 20.34 -41%
Consolidated Net Total Income 1546.49 1098.53 41%
|
Ipca Laboratories (in Rs. Cr.) |
Jun '20 |
Mar '20 |
Jun '19 |
YOY |
QOQ |
|
Net Sales |
1,534 |
1,074 |
1,078 |
42 |
43 |
|
P B T |
546.64 |
114.58 |
168.37 |
225 |
377 |
|
Tax |
99.89 |
29.2 |
37.35 |
167 |
242 |
|
Net Profit |
446.75 |
85.38 |
131.02 |
241 |
423 |
|
Minority Interest |
0.45 |
2.96 |
0.2 |
125 |
-84.8 |
|
Share Of P/L Of Associates |
-1.07 |
-2.33 |
-1.59 |
-32.7 |
-54.08 |
|
FINAL NPT |
446.13 |
86.01 |
129.63 |
244 |
419 |
|
25.27 |
25.27 |
25.27 |
0 |
0 |
|
|
Basic EPS |
35.27 |
6.57 |
10.24 |
244 |
437 |
|
MP |
2005 |
||||
|
PE |
14.22 |
||||
|
VOLUMES |
209000 |
||||
|
52 Wk L/H |
844.2 |
2175 |
|
Annual |
Mar-20 |
Mar-19 |
Mar-18 |
Mar-17 |
Mar-16 |
|
Sales |
4,649 |
3,773 |
3,258 |
3,156 |
2,867 |
|
Net Profit |
611.37 |
444.03 |
243.65 |
202.8 |
96.2 |
|
Historical Prices |
|||
|
3M BEF |
Current Price |
%Gain / Loss |
|
|
Open Price |
1596 |
2032.25 |
27.33 |
|
1YR BEF |
|||
|
Open Price |
969 |
2032.25 |
109.73 |
|
2YR BEF |
|||
|
Open Price |
725.8 |
2032.25 |
180 |
|
3YR BEF |
|||
|
Open Price |
414 |
2032.25 |
390.88 |
|
Share Holding Pattern in (%) |
||||
|
Standalone |
Jun-20 |
Mar-20 |
Sep-19 |
Jun-19 |
|
Promoters |
46.07 |
46.07 |
46.07 |
46.07 |
|
Pledged |
0 |
0 |
0 |
0 |
|
FII/FPI |
12.39 |
12.64 |
16.14 |
15.58 |
|
Total DII |
31 |
30.62 |
26.89 |
27.64 |
|
Fin.Insts |
0.03 |
0.04 |
0.04 |
0.03 |
|
Insurance Co |
4.23 |
2.22 |
0.78 |
0 |
|
MF |
22.82 |
23.14 |
21.52 |
22.25 |
|
Others DIIs |
3.92 |
5.22 |
4.55 |
5.36 |
|
Others |
10.54 |
10.66 |
10.9 |
10.7 |
|
Total |
100 |
99.99 |
100 |
99.99 |
